Scandinavia looks like it should behave as one region: four wealthy public health systems, similar psychiatry, similar drug regulators. Instead, Norway, Sweden, Denmark and Finland have reached four genuinely different answers on esketamine and ketamine therapy — including the only decision of its kind in the world. This guide compares the four systems side by side (strictly speaking, Finland makes this the Nordics rather than Scandinavia — patients searching rarely make that distinction, so we cover all four), using what our country guides and directory records document. For any single country, the full picture lives in the dedicated guide linked below.
TL;DR Norway publicly funds generic IV ketamine for treatment-resistant depression — a world first, decided 25 August 2025 — and rejected Spravato three times. Sweden never rejected Spravato but its NT Council recommends "strongly restrained" use, with each of 21 regions deciding its own funding. Denmark's Medicinrådet recommended Spravato in November 2025 for roughly 40–60 patients a year after at least three failed treatments. Finland has reimbursed Spravato through Kela since August 2023 under the strictest criteria in Europe, paired with a uniquely flexible pharmacy-dispensing model. Private ketamine clinics are essentially an Oslo phenomenon. Trials are recruiting in Sweden, Denmark and Norway; reimbursement does not cross any of these borders.
At a glance
| Publicly funded route | Private ketamine market | Trials recruiting | In our directory | |
|---|---|---|---|---|
| Norway | Generic IV ketamine for TRD since 25 August 2025 — a world first; Spravato rejected three times | Two established Oslo clinics with published prices | One ketamine study (Tromsø) | 4 records |
| Sweden | Spravato legal but "strongly restrained" per the NT Council; each of 21 regions decides funding | Off-label ketamine in some specialist and private settings; only Region Jönköping publishes a tariff (2,089–6,269 SEK per session) | Psilocybin studies in five cities | 7 records |
| Denmark | Spravato recommended by Medicinrådet in November 2025 (≥3 failed treatments; ~40–60 patients/year), plus an acute-crisis route since January 2023 | No private ketamine-clinic market to speak of | Psilocybin studies at two Copenhagen hospitals | 2 records |
| Finland | Spravato Kela-reimbursed since August 2023 — Europe's strictest criteria (MADRS ≥31, three failed treatments incl. psychotherapy) | No established private infusion market; supervised esketamine also runs in private outpatient units | None currently | 3 records |
Country detail: Norway · Sweden · Denmark · Finland
Norway: the world first — and the Spravato inversion
Norway holds a distinction no other country has: since 25 August 2025, its public health system funds intravenous generic racemic ketamine for treatment-resistant depression, decided by Beslutningsforum (Nye Metoder, ID2022_018) and effective the same day. The decision comes with conditions that define the route: treatment in the public specialist service only (hospitals and DPS centres), written consent acknowledging off-label use, registry or study follow-up for every patient, and a re-evaluation by the end of 2028. The way in is the standard referral chain — your fastlege refers you to specialist mental health care, with a written treatment history doing most of the work.
The inversion is what makes Norway instructive: the licensed product, Spravato, is the one that is not funded — Beslutningsforum rejected it three times between 2021 and 2022 on evidence and price, and declined a reassessment in 2025. Most of Europe funds the branded spray and leaves generic ketamine to the private market; Norway did the opposite.
The private market still exists alongside: two established Oslo clinics, listed in our Norway catalog, publish their prices — sessions at roughly NOK 4,250–7,590, complete programmes from about NOK 12,750 to 47,640 — which makes Oslo the one Nordic city with a visible self-pay ketamine market. Full detail: Psychedelic therapy in Norway and Is ketamine publicly funded in Norway?
Sweden: restraint by design
Sweden never said no to Spravato — it said "not so fast," and keeps saying it. The NT Council, which advises all 21 regions, recommends kraftigt återhållsam (strongly restrained) use of esketamine — a recommendation first issued 30 June 2021 and revised 6 November 2024 (Samverkanläkemedel). In practice that means Spravato becomes relevant only after roughly four failed treatment alternatives, counting antidepressants, augmentation and, where appropriate, ECT — and because each region decides its own funding, the same diagnosis can meet a different answer in a different county.
Off-label racemic ketamine occupies a quiet middle ground: used for depression in some specialist and private settings, with exactly one officially published price — Region Jönköping's dose-based tariff of 2,089–6,269 SEK per session. Where Sweden genuinely stands out is research: psilocybin trials are recruiting in Stockholm, Gothenburg, Uppsala, Örebro and Lund, which makes the Swedish research route one of the most open in Europe. Full detail: Psychedelic therapy in Sweden and Is Spravato reimbursed in Sweden?
Denmark: a November 2025 reversal, rolling out from a low base
Denmark spent five years as a Spravato holdout, then changed its mind on evidence. On 19 November 2025, Medicinrådet recommended esketamine for adults with moderate-to-severe treatment-resistant depression after at least three failed antidepressant treatments in the current episode — reversing its 2020 rejection after new 32-week data and a lower price (Medicinrådet). The scale is deliberately modest: roughly 40–60 patients per year, treated within regional hospital psychiatry. A separate recommendation has covered esketamine since January 2023 as acute short-term treatment for admitted patients with acutely increased suicide risk.
What Denmark does not have is a private route: no ketamine-clinic market to speak of, and no legal access to psilocybin or MDMA outside authorised research. What it does have is a research scene stronger than its size suggests — psilocybin studies recruiting at Rigshospitalet and Bispebjerg in Copenhagen, and 12 Denmark-linked trials tracked, 7 of them active. Full detail: Psychedelic therapy in Denmark and Is Spravato reimbursed in Denmark?
Finland: the strictest gate, the most flexible door
Finland reimburses Spravato through Kela under two restricted entitlements introduced from August 2023 — code 3062 (basic reimbursement, 40 per cent of the medicine) and code 1539 (special reimbursement, 100 per cent) — with the strictest published criteria in Europe: a MADRS score of at least 31 at the start, at least three failed antidepressant treatments with attached psychotherapy or other psychosocial care, one of them a combination treatment, all documented in a psychiatrist's B-statement (Kela 3062, Kela 1539). The entitlement is time-limited to one year, continued only if MADRS scores have at least halved.
The counterweight is Europe's most flexible delivery model: the patient buys the reimbursed spray at a pharmacy and self-administers it under supervision at a healthcare unit — which is why, unusually for the Nordics, supervised esketamine treatment also runs in private outpatient settings, and why our Finland catalog lists private clinics in Helsinki and Turku rather than hospital departments. There is no established private ketamine-infusion market, and no Finnish psychedelic trial is currently recruiting. Full detail: Psychedelic therapy in Finland and Is Spravato reimbursed in Finland?
Crossing borders in the Nordics
Two rules hold across all four countries. First, reimbursement does not travel: each system funds treatment inside its own specialist service, under its own criteria, for its own residents — a Swede cannot claim Norway's public ketamine pathway, and a Dane cannot use Kela codes. The mechanics of who pays for what across Europe are in our reimbursement map. Second, trials are the one genuinely open cross-border door: participation is free wherever you enrol, and screening for a study can run in parallel with a public referral at home — the trials guide explains how phases, placebo and consent work.
The honest common denominator is documentation. Whatever the country, the document that decides cases is a written treatment history: every antidepressant tried in the current episode, with substance, dose, duration and outcome. The bar it must clear differs — two failures in most of Europe, three in Denmark and Finland, roughly four alternatives in Sweden — but the homework is identical, and it is worth doing before any first appointment. Our eligibility check sorts the questions in order.
Frequently asked questions
Which Scandinavian country publicly funds ketamine therapy?
Norway — and it is the only country in the world that does. Since 25 August 2025, generic IV racemic ketamine for treatment-resistant depression is publicly funded, delivered in public hospitals and DPS centres with off-label consent and registry follow-up. The other three fund the licensed esketamine spray (Spravato) instead, each under its own criteria.
Is Spravato reimbursed in Norway?
No. Beslutningsforum rejected it three times between 2021 and 2022 and declined a reassessment in 2025. Norway channelled this patient group toward the publicly funded generic IV ketamine pathway instead.
Where in the Nordics are trials recruiting?
As of August 2026 our country guides document psilocybin studies recruiting in five Swedish cities (Stockholm, Gothenburg, Uppsala, Örebro, Lund) and at two Copenhagen hospitals (Rigshospitalet and Bispebjerg), plus a ketamine study in Tromsø, Norway. Finland has no recruiting psychedelic trial. Participation is free, screening is strict, and enrolment is never guaranteed.
Can I get treatment in a neighbouring Nordic country?
Not on public funding — each system reimburses inside its own borders. The realistic cross-border options are self-pay private treatment where a market exists (essentially Oslo for ketamine infusions) and clinical trials, which are free wherever you qualify and enrol.
What does private ketamine treatment cost in Scandinavia?
Oslo is the reference point, because it is where prices are published: roughly NOK 4,250–7,590 per session and complete programmes from about NOK 12,750 to 47,640. In Sweden the only published figure is Region Jönköping's official tariff of 2,089–6,269 SEK per session; named private clinics publish no prices. Denmark and Finland have no established private infusion market. For the continent-wide picture, see the cost guide.
Sources
- Nye Metoder, ID2022_018 — decision on ketamine for treatment-resistant depression (Norway)
- Psychedelic Alpha: Norway approves public funding for generic ketamine in treatment-resistant depression
- Nye Metoder, ID2019_116 — esketamine (Spravato) assessments (Norway)
- Samverkanläkemedel: NT Council recommendation on Spravato (esketamine)
- Medicinrådet: recommendation on esketamine for severe treatment-resistant depression (November 2025)
- Kela: restricted basic reimbursement 3062 (esketamine)
- Kela: restricted special reimbursement 1539 (esketamine)
- Blossom: Norway country report
- ClinicalTrials.gov: NCT06090422 — KeDA ketamine study, Tromsø
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Regulations and reimbursement rules change; always verify current requirements with the national authority or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.